연구동향 분석
박사

Analysis of circulating tumor DNA for clinical application

신승호 2019년

논문상세정보
인용/피인용
' Analysis of circulating tumor DNA for clinical application' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Cancer genomics
  • Circulating tumor DNA
  • Liquid biopsy
  • Next Generation Sequencing
  • cellfreedna
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
88 0

0.0%

' Analysis of circulating tumor DNA for clinical application' 의 참고문헌

  • Zeng, Y. & Feldman, A.L. Genetics of anaplastic large cell lymphoma. Leuk Lymphoma 57, 21-7 (2016).
  • Yang, Y.T. et al. Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review. PLoS One 11, e0161811 (2016).
  • Yang, N. et al. The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues. BMC Cancer 18, 319 (2018).
  • Xu, R.-h. et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature materials 16, 1155 (2017).
  • Wu, C. et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget 7, 38180-38190 (2016).
  • Walter, M.J. et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366, 1090-8 (2012).
  • Vardiman, J.W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937-51 (2009).
  • Van Heertum, R.L. et al. Lugano 2014 criteria for assessing FDGPET/ CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther 11, 1719-1728 (2017).
  • Valentine, M.R., Rodriguez, H. & Termini, J. Mutagenesis by peroxy radical is dominated by transversions at deoxyguanosine: evidence for the lack of involvement of 8-oxo-dG1 and/or abasic site formation. Biochemistry 37, 7030-8 (1998).
  • Vaca-Paniagua, F. et al. Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing. Epigenomics 7, 353-362 (2015).
  • Tsui, N.B. et al. High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS One 7, e48319 (2012).
  • Tollervey, J.R. & Lunyak, V.V. Epigenetics: judge, jury and executioner of stem cell fate. Epigenetics 7, 823-840 (2012).
  • Tokheim, C.J., Papadopoulos, N., Kinzler, K.W., Vogelstein, B. & Karchin, R. Evaluating the evaluation of cancer driver genes. Proc Natl Acad Sci U S A 113, 14330-14335 (2016).
  • Tie, J. et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Annals of Oncology 26, 1715-1722 (2015).
  • Teschendorff, A.E., Breeze, C.E., Zheng, S.C. & Beck, S. A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. BMC Bioinformatics 18, 105 (2017).
  • Takai, E. et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Scientific reports 5, 18425 (2015).
  • Swerdlow, S.H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375-90 (2016).
  • Swerdlow, S.H. et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood, blood-2016-01- 643569 (2016).
  • Sun, K. et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proceedings of the National Academy of Sciences 112, E5503-E5512 (2015).
  • Stroun, M. et al. The origin and mechanism of circulating DNA. Annals of the New York Academy of Sciences 906, 161-168 (2000).
  • Snyder, M.W., Kircher, M., Hill, A.J., Daza, R.M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissuesof- origin. Cell 164, 57-68 (2016).
  • Shibutani, S., Takeshita, M. & Grollman, A.P. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349, 431-4 (1991).
  • Shankland, K.R., Armitage, J.O. & Hancock, B.W. Non-Hodgkin lymphoma. Lancet 380, 848-57 (2012).
  • Segal, M. Extracellular and cerebrospinal fluids. Journal of inherited metabolic disease 16, 617-638 (1993).
  • Schneider, G., Schmidt-Supprian, M., Rad, R. & Saur, D. Tissue-specific tumorigenesis: context matters. Nature Reviews Cancer 17, 239 (2017).
  • Schmitt, M.W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A 109, 14508-13 (2012).
  • Schirmer, M. et al. Insight into biases and sequencing errors for amplicon sequencing with the Illumina MiSeq platform. Nucleic Acids Res 43, e37 (2015).
  • Sakata-Yanagimoto, M., Enami, T., Yokoyama, Y. & Chiba, S. Diseasespecific mutations in mature lymphoid neoplasms: recent advances. Cancer Sci 105, 623-9 (2014).
  • Sakata-Yanagimoto, M. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46, 171-5 (2014).
  • Sakata-Yanagimoto, M. et al. Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. Ann Hematol 96, 1471-1475 (2017).
  • Rossi, D. et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 129, 1947-1957 (2017).
  • Rosenthal, A. & Younes, A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev 31, 37-42 (2017).
  • Roschewski, M. et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16, 541-9 (2015).
  • Renshaw, A.A., Dean, B.R., Cibas, E.S., Antman, K.H. & Sugarbaker, D.J. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 111, 106-109 (1997).
  • Rainer, T.H. et al. Comparison of plasma beta-globin DNA and S-100 protein concentrations in acute stroke. Clin Chim Acta 376, 190-6 (2007).
  • Quigley, D. et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer discovery (2017).
  • Qu, W., Hashimoto, S. & Morishita, S. Efficient frequency-based de novo short-read clustering for error trimming in next-generation sequencing. Genome Res 19, 1309-15 (2009).
  • Pitterl, F., Chervet, J.P. & Oberacher, H. Electrochemical simulation of oxidation processes involving nucleic acids monitored with electrospray ionization-mass spectrometry. Anal Bioanal Chem 397, 1203-15 (2010).
  • Phallen, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Science translational medicine 9, eaan2415 (2017).
  • Phallen, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 9(2017).
  • Pastore, A. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16, 1111-1122 (2015).
  • Pasqualucci, L. et al. Hypermutation of multiple proto-oncogenes in Bcell diffuse large-cell lymphomas. Nature 412, 341-6 (2001).
  • Parkinson, C.A. et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS medicine 13, e1002198 (2016).
  • Park, G. et al. Characterization of background noise in capture-based targeted sequencing data. Genome Biol 18, 136 (2017).
  • Pan, W., Gu, W., Nagpal, S., Gephart, M.H. & Quake, S.R. Brain tumor mutations detected in cerebral spinal fluid. Clinical chemistry, clinchem. 2014.235457 (2015).
  • Pai, S.G. et al. Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer. J Gastrointest Oncol 8, 858- 866 (2017).
  • Ong, K., Indumathi, V., Poh, W. & Ong, Y. The diagnostic yield of pleural fluid cytology in malignant pleural effusions. Singapore medical journal 41, 19-23 (2000).
  • O'Connor, O.A. & Tobinai, K. Putting the clinical and biological heterogeneity of non-hodgkin lymphoma into context. Clin Cancer Res 20, 5173-81 (2014).
  • Norton, S.E., Lechner, J.M., Williams, T. & Fernando, M.R. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem 46, 1561-5 (2013).
  • Newman, A.M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature biotechnology 34, 547 (2016).
  • Newman, A.M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34, 547-555 (2016).
  • Newman, A.M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature medicine 20, 548 (2014).
  • Neeley, W.L. & Essigmann, J.M. Mechanisms of formation, genotoxicity, and mutation of guanine oxidation products. Chem Res Toxicol 19, 491- 505 (2006).
  • Navada, S., Lai, P., Schwartz, A. & Kalemkerian, G. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. Journal of Clinical Oncology 24, 7082-7082 (2006).
  • Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E. & Adjei, A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. in Mayo Clinic Proceedings Vol. 83 584-594 (Elsevier, 2008).
  • Moffitt, A.B. & Dave, S.S. Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma. J Clin Oncol 35, 955-962 (2017).
  • Mitsudomi, T. & Yatabe, Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. Febs j 277, 301-8 (2010).
  • Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-6 (2012).
  • Minoche, A.E., Dohm, J.C. & Himmelbauer, H. Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol 12, R112 (2011).
  • McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297-303 (2010).
  • McBride, T.J., Preston, B.D. & Loeb, L.A. Mutagenic spectrum resulting from DNA damage by oxygen radicals. Biochemistry 30, 207-13 (1991).
  • Manso, R. et al. The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. Blood 123, 2893-4 (2014).
  • Mandel, P. Les acides nucleiques du plasma sanguin chez 1 homme. CR Seances Soc Biol Fil 142, 241-243 (1948).
  • Mamanova, L. et al. Target-enrichment strategies for next-generation sequencing. Nat Methods 7, 111-8 (2010).
  • Lyu, G.Y., Yeh, Y.H., Yeh, Y.C. & Wang, Y.C. Mutation load estimation model as a predictor of the response to cancer immunotherapy. NPJ Genom Med 3, 12 (2018).
  • Lui, Y.Y. et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clinical chemistry 48, 421-427 (2002).
  • Lui, Y.Y. et al. Origin of plasma cell-free DNA after solid organ transplantation. Clin Chem 49, 495-6 (2003).
  • Louissaint, A., Jr. et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood 128, 1093-100 (2016).
  • Lo, Y.M., Rainer, T.H., Chan, L.Y., Hjelm, N.M. & Cocks, R.A. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 46, 319-23 (2000).
  • Liu, X. et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. Journal of clinical pathology 66, 1065-1069 (2013).
  • Lim, M.S. & Elenitoba-Johnson, K.S. Precision Medicine for Diffuse Large B-cell Lymphoma. Clin Cancer Res 22, 2829-31 (2016).
  • Li, Y., Wang, Y., Wang, Z., Yi, D. & Ma, S. Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol 39, 8- 13 (2015).
  • Li, W. et al. CancerDetector: ultrasensitive and non-invasive cancer detection at the resolution of individual reads using cell-free DNA methylation sequencing data. Nucleic acids research (2018).
  • Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-9 (2009).
  • Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 27, 2987-93 (2011).
  • Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows103 Wheeler transform. Bioinformatics 26, 589-95 (2010).
  • Leon, S., Shapiro, B., Sklaroff, D. & Yaros, M. Free DNA in the serum of cancer patients and the effect of therapy. Cancer research 37, 646-650 (1977).
  • Lehmann-Werman, R. et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proceedings of the National Academy of Sciences 113, E1826-E1834 (2016).
  • Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
  • Lai, H.S. et al. Bone marrow involvement in non-Hodgkin's lymphoma. Taiwan Yi Xue Hui Za Zhi 88, 114-21 (1989).
  • Laehnemann, D., Borkhardt, A. & McHardy, A.C. Denoising DNA deep sequencing data-high-throughput sequencing errors and their correction. Brief Bioinform 17, 154-79 (2016).
  • Kurtz, D.M. et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125, 3679-87 (2015).
  • Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317-30 (2015).
  • Kuchta, R.D., Benkovic, P. & Benkovic, S.J. Kinetic mechanism whereby DNA polymerase I (Klenow) replicates DNA with high fidelity. Biochemistry 27, 6716-25 (1988).
  • Krueger, F. & Andrews, S.R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. bioinformatics 27, 1571-1572 (2011).
  • Klein, U. et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 162, 261-80 (1998).
  • Kino, K. & Sugiyama, H. UVR-induced G-C to C-G transversions from oxidative DNA damage. Mutat Res 571, 33-42 (2005).
  • Kino, K. & Sugiyama, H. Possible cause of G-C-->C-G transversion mutation by guanine oxidation product, imidazolone. Chem Biol 8, 369- 78 (2001).
  • Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K.W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proceedings of the National Academy of Sciences 108, 9530-9535 (2011).
  • Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K.W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 108, 9530-5 (2011).
  • Kim, S. et al. Strelka2: Fast and accurate variant calling for clinical sequencing applications. bioRxiv, 192872 (2017).
  • Kim, J.Y. et al. Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. Oncotarget 8, 86423- 86434 (2017).
  • Kang, S. et al. CancerLocator: non-invasive cancer diagnosis and tissueof- origin prediction using methylation profiles of cell-free DNA. Genome biology 18, 53 (2017).
  • Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-9 (2013).
  • Johnson, P. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. Journal of gastroenterology and hepatology 14, S32-S36 (1999).
  • Jiang, M., Bennani, N.N. & Feldman, A.L. Lymphoma classification update: B-cell non-Hodgkin lymphomas. Expert Rev Hematol 10, 405-415 (2017).
  • Irizarry, R.A. et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nature genetics 41, 178 (2009).
  • Husain, H. et al. Cell-free DNA from ascites and pleural effusions: Molecular insights into genomic aberrations and disease biology. Molecular cancer therapeutics 16, 948-955 (2017).
  • Hong, J. et al. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma. Acta Haematol 130, 305-11 (2013).
  • Hench, I.B., Hench, J. & Tolnay, M. Liquid biopsy in clinical management of breast, lung, and colorectal cancer. Frontiers in medicine 5, 9 (2018).
  • Heitzer, E., Ulz, P. & Geigl, J.B. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61, 112-23 (2015).
  • Hansen, K.D., Langmead, B. & Irizarry, R.A. BSmooth: from whole genome bisulfite sequencing reads to differentially methylated regions. Genome biology 13, R83 (2012).
  • Guo, S. et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-oforigin mapping from plasma DNA. Nature genetics 49, 635 (2017).
  • Gundry, M. & Vijg, J. Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants. Mutat Res 729, 1-15 (2012).
  • Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 27, 182-9 (2009).
  • Gibney, G.T., Weiner, L.M. & Atkins, M.B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17, e542-e551 (2016).
  • Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883-92 (2012).
  • Garcia, P.D. et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res 20, 1834-45 (2014).
  • Foucar, K., McKenna, R.W., Frizzera, G. & Brunning, R.D. Bone marrow and blood involvement by lymphoma in relationship to the Lukes-- Collins classification. Cancer 49, 888-97 (1982).
  • Forbes, S.A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic acids research 45, D777-D783 (2016).
  • Fan, H.C., Blumenfeld, Y.J., Chitkara, U., Hudgins, L. & Quake, S.R. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A 105, 16266-71 (2008).
  • Dohm, J.C., Lottaz, C., Borodina, T. & Himmelbauer, H. Substantial biases in ultra-short read data sets from high-throughput DNA sequencing. Nucleic Acids Res 36, e105 (2008).
  • Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102, 16368- 73 (2005).
  • Diaz, L.A., Jr. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-40 (2012).
  • Diaz, L.A., Jr. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32, 579-86 (2014).
  • De Mattos-Arruda, L. et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature communications 6, 8839 (2015).
  • Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res 41, e67 (2013).
  • Coletta, D.F. & Siegel, P.D. Lactic Dehydrogenase. Med Sci 15, 98-101 (1964).
  • Cohen, J.D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, eaar3247 (2018).
  • Cline, J., Braman, J.C. & Hogrefe, H.H. PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res 24, 3546-51 (1996).
  • Chung, J. et al. The minimal amount of starting DNA for Agilent’s hybrid capture-based targeted massively parallel sequencing. Scientific reports 6, 26732 (2016).
  • Chung, J. et al. The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing. Sci Rep 6, 26732 (2016).
  • Christensen, E. et al. Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Scientific reports 8, 1917 (2018).
  • Cheng, T.H. et al. Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clinical biochemistry 50, 496-501 (2017).
  • Cheng, D.T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn 17, 251-64 (2015).
  • Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220- 1222 (2015).
  • Chaudhuri, A.A. et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer discovery (2017).
  • Chang, M.T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature biotechnology 34, 155 (2016).
  • Chang, M.T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34, 155-63 (2016).
  • Chalmers, Z.R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9, 34 (2017).
  • Cedar, H. & Bergman, Y. Programming of DNA methylation patterns. Annual review of biochemistry 81, 97-117 (2012).
  • Castellar, E.R.P. et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124, 1473-1480 (2014).
  • Campo, E., Raffeld, M. & Jaffe, E.S. Mantle-cell lymphoma. in Seminars in hematology Vol. 36 115-127 ([Sheboygan, Wis.]: Grune & Stratton,[c1964-, 1999).
  • Campesato, L.F. et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget 6, 34221-7 (2015).
  • Camicia, R., Winkler, H.C. & Hassa, P.O. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large Bcell lymphoma: a comprehensive review. Mol Cancer 14, 207 (2015).
  • Cairns, R.A. et al. IDH2 mutations are frequent in angioimmunoblastic Tcell lymphoma. Blood 119, 1901-3 (2012).
  • Braggio, E., Egan, J.B., Fonseca, R. & Stewart, A.K. Lessons from nextgeneration sequencing analysis in hematological malignancies. Blood Cancer Journal 3(2013).
  • Bettegowda, C. et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Science translational medicine 6, 224ra24-224ra24 (2014).
  • Berinstein, N.L. et al. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. J Clin Oncol 11, 1344-52 (1993).
  • Baylin, S.B. & Jones, P.A. Epigenetic determinants of cancer. Cold Spring Harbor perspectives in biology, a019505 (2016).
  • Alix-Panabieres, C. & Pantel, K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov 6, 479-91 (2016).
  • Akasaka, S. & Yamamoto, K. Mutagenesis resulting from DNA damage by lipid peroxidation in the supF gene of Escherichia coli. Mutat Res 315, 105-12 (1994).
  • A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329, 987-94 (1993).